默克公司于2023年启动了多项3期试验:更新后的预期包括MK-6024,一种GLP-1/胰高血糖素受体双重激动剂,已进入治疗非酒精性脂肪性肝炎(MASH)的2b期临床。它还增加了对sotatercept和MK-0616的信心,sotatercept正在接受FDA对肺动脉高压的优先审查,而MK-0616是一种口服PCSK9抑制剂。 表3: sotatercept和MK-0616美国c...
本文分子为Merck公司Ⅱ期临床环肽药物MK-0616 的结构类似物。拟肽类化合物以酰胺键连接各个片段,故在逆合成时通常作断键优选。多肽化合物通过氨基酸的C/N端单保护成肽键后脱保护如此反复而得,肽键构建其在方法上没有太多花样;但大环化合物成环却很有难度。 阅读本文可知文章写作以实验操作和处理为描述之重,例如加...
【医学同传前沿】本周三个Merck/MSD的临床试验研究者会议同传,涉及的药物有MK-6024、MK-8521、MK-1462、Sotorasib、Adagrasib、LY3537982、Pembrolizumab、GDC-6036 (divarasib)、MK-1084、Statin、Bempedoic Acid、MK-0616,核心药物MK-6024、MK-1084、MK-0616,药物类别KRAS G12C抑制剂、GLP-1-based Co-agonists...
Resultsfrom the Phase 2b clinical trial evaluating MK-0616, an investigational once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in adults with hypercholesterolemia. MK-0616 significantly reduced low-density lipoprotein cholesterol (LDL-C) across all dose levels compared to...
Now, Merck has presented data at the American Heart Association Meeting on its experimental drug MK-0616, which is also a PCSK9 inhibitor, according to BioSpace. Repatha and Praluent may face a big challenge if Merck is able to bring its drug to the finishing line, which is now...
enlicitide decanoate (MK-0616) VJL JCY MAW SEL WLN CWE JCY WLN YGL DTV ZOY BPC sacituzumab tirumotecan (MK-2870) IML FPB KLJ PYS KEU ITR PCR WVX PQH JCY OWL WVX mRNA-4157 (V940) VJV WAZ BPC DTV WUV BPC NYK KLJ PQH ITR tulisokibart JCY WVX UAI ITR LAF LYX YGL IML BPC...
PBMK04710 B300K 47MM HIGH FLUX 10PK PBMK06210 B300K 63.5MM HIGH FLUX 10PK PBMK07610 B300K 76MM HIGH FLUX 10PK PBMK09005 B300K 90MM HIGH FLUX 5PK PBMK15005 B300K 150MM HIGH FLUX 5PK PBQK02510 B50K 25MM HIGH FLUX 10PK PBQK04310 B50K 44.5MM HIGH FLUX 10PK. PBQK04710 B50K ...
PBMK04710 B300K 47MM HIGH FLUX 10PK PBMK06210 B300K 63.5MM HIGH FLUX 10PK PBMK07610 B300K 76MM HIGH FLUX 10PK PBMK09005 B300K 90MM HIGH FLUX 5PK PBMK15005 B300K 150MM HIGH FLUX 5PK PBQK02510 B50K 25MM HIGH FLUX 10PK PBQK04310 B50K 44.5MM HIGH FLUX 10PK. PBQK04710 B50K ...
2023年,默沙东针对Keytruda新开了多项联合治疗III期临床研究,其中包括与肿瘤mRNA疫苗V940(mRNA-4157)联合治疗非小细胞肺癌(NSCLC)的两项研究,以及与TROP2 ADC新药MK-2870(从科伦博泰引进)联合一线治疗NSCLC的关键III期研究。除了继续挖掘Keytruda与其他疗法联合的治疗潜力,默沙东还计划通过增补肿瘤产品管线进一步丰富产品群...
With these promising data showing that MK-0616 reduced LDL-C levels by up to 60.9%, MK-0616 should be further studied for its potential as a daily oral medicine.” “These data reinforce our confidence that MK-0616 could become the first ora...